PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1803362
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1803362
The global closed-system transfer devices (CSTDs) market was valued at USD 1.78 billion in 2024 and is expected to grow to USD 4.36 billion by 2032, advancing at a compound annual growth rate (CAGR) of 12.0% during 2025-2032. This growth is driven by the increasing global incidence of cancer, rising demand for chemotherapy drugs, and heightened awareness about the harmful effects of hazardous drugs like cytotoxic and antineoplastic agents used in cancer treatment. As the global population increases and cancer rates continue to rise, the demand for oncology drugs and the healthcare workers who handle them is also growing. These drugs can pose significant health risks to healthcare workers, making the use of CSTDs essential for maintaining safety.
Government initiatives and regulations, such as those from the European Union and the Israeli government, are promoting the use of CSTDs to reduce the exposure to hazardous drugs in healthcare settings. The growing emphasis on safety, infection control, and occupational health is further driving market growth.
Key Insights
Technological advancements in CSTDs are playing a key role in the market's growth. The development of needle-free systems and membrane-to-membrane technology is increasing the safety and efficiency of drug transfer processes. These advancements are helping reduce the risks associated with handling hazardous drugs, such as needlestick injuries and contamination from aerosols.
Chemotherapy is a significant driver of CSTDs demand due to the increasing number of cancer cases worldwide. According to the World Health Organization, cancer remains the leading cause of death globally, driving the need for safe drug delivery systems like CSTDs. As more patients undergo chemotherapy, the demand for these devices continues to rise.
Membrane-to-membrane systems accounted for the largest share (60%) of the market in 2024. These devices are highly efficient, with minimal drug loss and less chance of contamination, making them a preferred choice in healthcare facilities.
Needleless systems are expected to grow at a faster rate in the coming years, as the healthcare sector increasingly shifts towards safer, needle-free solutions to reduce the risk of accidental needlestick injuries.
The diaphragm-based technology held the largest market share (45%) in 2024, favored for its simplicity and effectiveness in preventing contamination. These systems are commonly used for chemotherapy drugs, which require strict safety measures due to their toxicity.
Hospitals and clinics remain the largest end-users of CSTDs, driven by the high volume of cancer patients treated in these settings. As hospitals are required to comply with strict safety regulations, the demand for CSTDs continues to increase.
The oncology centers segment is projected to grow at the highest CAGR of 13.5%, due to the growing number of cancer treatment centers and the rising demand for chemotherapy drugs. These centers specialize in handling hazardous drugs, making them key adopters of CSTDs.
North America held the largest market share (45%) in 2024, primarily driven by the high number of cancer cases in the U.S. and the presence of major manufacturers in the region. The U.S. healthcare system's emphasis on worker safety and regulatory compliance further supports the use of CSTDs in oncology and other medical settings.
Asia-Pacific (APAC) is expected to see the highest growth rate (13.5%) during the forecast period, driven by the rising cancer burden in countries like China and India, increased healthcare investments, and regulatory support for the use of CSTDs in drug administration.